Merck Other Long-Term Assets 2010-2024 | MRK

Merck other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Merck other long-term assets for the quarter ending September 30, 2024 were $14.443B, a 36.78% increase year-over-year.
  • Merck other long-term assets for 2023 were $11.996B, a 25.9% increase from 2022.
  • Merck other long-term assets for 2022 were $9.528B, a 17.73% decline from 2021.
  • Merck other long-term assets for 2021 were $11.582B, a 17.21% increase from 2020.
Merck Annual Other Long-Term Assets
(Millions of US $)
2023 $11,996
2022 $9,528
2021 $11,582
2020 $9,881
2019 $6,771
2018 $5,881
2017 $6,075
2016 $5,854
2015 $6,055
2014 $5,533
2013 $9,115
2012 $6,723
2011 $5,735
2010 $5,626
2009 $5,376
Merck Quarterly Other Long-Term Assets
(Millions of US $)
2024-09-30 $14,443
2024-06-30 $12,702
2024-03-31 $12,326
2023-12-31 $11,996
2023-09-30 $10,559
2023-06-30 $10,187
2023-03-31 $10,280
2022-12-31 $9,528
2022-09-30 $9,584
2022-06-30 $10,972
2022-03-31 $11,141
2021-12-31 $11,582
2021-09-30 $11,190
2021-06-30 $11,053
2021-03-31 $10,486
2020-12-31 $9,881
2020-09-30 $8,007
2020-06-30 $7,599
2020-03-31 $7,052
2019-12-31 $6,771
2019-09-30 $9,004
2019-06-30 $9,155
2019-03-31 $8,707
2018-12-31 $5,881
2018-09-30 $7,500
2018-06-30 $7,145
2018-03-31 $6,558
2017-12-31 $6,075
2017-09-30 $5,884
2017-06-30 $5,928
2017-03-31 $5,872
2016-12-31 $5,854
2016-09-30 $6,443
2016-06-30 $6,559
2016-03-31 $5,921
2015-12-31 $6,055
2015-09-30 $5,618
2015-06-30 $5,843
2015-03-31 $5,596
2014-12-31 $5,533
2014-09-30 $6,589
2014-06-30 $7,143
2014-03-31 $8,831
2013-12-31 $9,115
2013-09-30 $7,010
2013-06-30 $7,112
2013-03-31 $6,891
2012-12-31 $6,723
2012-09-30 $6,135
2012-06-30 $6,156
2012-03-31 $5,913
2011-12-31 $5,735
2011-09-30 $5,569
2011-06-30 $5,534
2011-03-31 $5,811
2010-12-31 $5,626
2010-09-30 $5,396
2010-06-30 $5,030
2010-03-31 $5,528
2009-12-31 $5,376
2009-09-30 $4,997
2009-06-30 $6,332
2009-03-31 $6,401
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $250.889B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $710.098B 73.55
Novo Nordisk (NVO) Denmark $471.460B 34.00
Johnson & Johnson (JNJ) United States $373.591B 15.15
AbbVie (ABBV) United States $312.696B 16.46
Novartis AG (NVS) Switzerland $213.148B 14.17
AstraZeneca (AZN) United Kingdom $203.493B 17.32
Pfizer (PFE) United States $145.358B 9.94
Sanofi (SNY) $122.526B 11.10
Innoviva (INVA) United States $1.199B 9.97